Should I buy or sell Liquidia stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LQDA shares. View LQDA analyst ratings or view top-rated stocks .

What is Liquidia's stock price target for 2024?

5 Wall Street analysts have issued 1-year price objectives for Liquidia's stock. Their LQDA share price targets range from $3.00 to $30.00. On average, they anticipate the company's share price to reach $16.67 in the next twelve months. This suggests a possible upside of 38.5% from the stock's current price. View analysts price targets for LQDA or view top-rated stocks among Wall Street analysts .

How have LQDA shares performed in 2023?

Liquidia's stock was trading at $6.37 on January 1st, 2023. Since then, LQDA shares have increased by 88.9% and is now trading at $12.03. View the best growth stocks for 2023 here .

When is Liquidia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024. View our LQDA earnings forecast .

How were Liquidia's earnings last quarter?

Liquidia Co. (NASDAQ:LQDA) released its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04. The business had revenue of $3.68 million for the quarter, compared to analyst estimates of $4.55 million. Liquidia had a negative net margin of 314.38% and a negative trailing twelve-month return on equity of 82.05%.

What ETF holds Liquidia's stock ?

Virtus LifeSci Biotech Clinical Trials ETF holds 13,817 shares of LQDA stock, representing 0.92% of its portfolio.

What other stocks do shareholders of Liquidia own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia investors own include VBI Vaccines (VBIV) , OPKO Health (OPK) , Aldeyra Therapeutics (ALDX) , Sorrento Therapeutics (SRNE) , vTv Therapeutics (VTVT) , Genocea Biosciences (GNCA) , Inovio Pharmaceuticals (INO) , AbbVie (ABBV) , Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA) .

When did Liquidia IPO?

(LQDA) raised $50 million in an initial public offering (IPO) on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.

How do I buy shares of Liquidia?

Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:LQDA

Liquidia (LQDA) Stock Price, News & Analysis

$12.03

-0.04 (-0.33%)

(As of 12/29/2023 ET)

Compare

Today's Range: $11.92
▼
$12.36
50-Day Range: $6.12
▼
$12.19
52-Week Range: $5.67
▼
$12.36

Volume: 788,490 shs
Average Volume: 1.85 million shs
Market Capitalization: $780.75 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.67

Liquidia MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.60 Rating Score
Upside/Downside: 38.5% Upside
$16.67 Price Target
Short Interest: Bearish
6.33% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.01
Based on 7 Articles This Week
Insider Trading: Acquiring Shares
$9 M Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.02) to ($0.86) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.36 out of 5 stars

Medical Sector

363rd out of 950 stocks

Pharmaceutical Preparations Industry

176th out of 442 stocks

3.3

Analyst's Opinion

Consensus Rating
Liquidia has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 4 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $16.67, Liquidia has a forecasted upside of 38.5% from its current price of $12.03.
Amount of Analyst Coverage
Liquidia has only been the subject of 4 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
6.33% of the outstanding shares of Liquidia have been sold short.
Short Interest Ratio / Days to Cover
Liquidia has a short interest ratio ("days to cover") of 4.9.
Change versus previous month
Short interest in Liquidia has recently decreased by 1.67%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Liquidia does not currently pay a dividend.
Dividend Growth
Liquidia does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for LQDA.

3.9

News and Social Media Coverage

News Sentiment
Liquidia has a news sentiment score of 1.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.84 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Liquidia this week, compared to 2 articles on an average week.
Search Interest
11 people have searched for LQDA on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.
MarketBeat Follows
8 people have added Liquidia to their MarketBeat watchlist in the last 30 days.

4.2

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Liquidia insiders have bought 213,625.91% more of their company's stock than they have sold. Specifically, they have bought $8,999,998.00 in company stock and sold $4,211.00 in company stock.
Percentage Held by Insiders
31.60% of the stock of Liquidia is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
45.03% of the stock of Liquidia is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Liquidia are expected to grow in the coming year, from ($1.02) to ($0.86) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Liquidia is -13.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Liquidia is -13.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Liquidia has a P/B Ratio of 8.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Liquidia Stock (NASDAQ:LQDA)

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension. The company distributes generic treprostinil injection in the United States. Liquidia Corporation was founded in 2004 and is headquartered in Morrisville, North Carolina.

LQDA Stock Price History

30 days | 90 days | 365 days | Advanced Chart

LQDA Stock News Headlines

December 30, 2023 | marketbeat.com

MarketBeat Week in Review: 12/25 - 12/29 (LQDA)

The Santa Claus rally took the S&P 500 up about 0.75%, but recession concerns linger as the full impact of the Fed's rate hikes hasn't hit the economy.

December 27, 2023 | marketbeat.com

Liquidia: Court victory the awakening of an industry giant?

Liquidia's stock surged after an enormous court win against United Therapeutics, accompanied by analyst upgrades and insider buying.

December 31, 2023 | MarketBeat Internal (Ad)

Claim Your $300 MarketBeat Account Credit

Click the link below to claim your $300.00 account credit toward MarketBeat All Access. Pay just $99.00 for your 2024 MarketBeat All Access subscription (normally $399.00)

December 25, 2023 | americanbankingnews.com

Wedbush Analysts Boost Earnings Estimates for Liquidia Co. (NASDAQ:LQDA)

December 23, 2023 | americanbankingnews.com

Liquidia (NASDAQ:LQDA) Reaches New 52-Week High Following Analyst Upgrade

December 22, 2023 | markets.businessinsider.com

Buy Rating for Liquidia Technologies Amid Legal Victory and Market Potential for YUTREPIA

December 22, 2023 | seekingalpha.com

Liquidia jumps on win in patent case against United Therapeutics (update)

December 22, 2023 | finance.yahoo.com

Industry Analysts Just Upgraded Their Liquidia Corporation (NASDAQ:LQDA) Revenue Forecasts By 38%

December 31, 2023 | MarketBeat Internal (Ad)

MarketBeat All Access New Year's Sale - Just $1.00

Access our premier research platform that includes MarketBeat Daily Premium, portfolio monitoring tools, stock screeners, research tools, a real-time news feed, email and SMS alerts, the MarketBeat Idea Engine, proprietary brokerage rankings, extended data export tools and much more. Save 75% Your 2024 Subscription. Just $1.00 for the first 30 days.

December 22, 2023 | americanbankingnews.com

Liquidia (NASDAQ:LQDA) Given Underperform Rating at Wedbush

December 22, 2023 | americanbankingnews.com

Liquidia (NASDAQ:LQDA) PT Raised to $15.00 at Bank of America

December 22, 2023 | americanbankingnews.com

LADENBURG THALM/SH SH Increases Liquidia (NASDAQ:LQDA) Price Target to $30.00

December 22, 2023 | americanbankingnews.com

Stock Traders Buy Large Volume of Call Options on Liquidia (NASDAQ:LQDA)

December 21, 2023 | markets.businessinsider.com

B of A Securities Maintains Buy Rating for Liquidia: Here's What You Need To Know

December 21, 2023 | markets.businessinsider.com

Analysts Are Bullish on Top Healthcare Stocks: Liquidia Technologies (LQDA), Oscar Health (OSCR)

December 21, 2023 | finance.yahoo.com

Independent Director of Liquidia Picks Up 5.3% More Stock

December 21, 2023 | markets.businessinsider.com

Buy Rating Affirmed for Liquidia Technologies Following Legal Victory and Anticipated FDA Approvals

December 20, 2023 | benzinga.com

Liquidia Stock (NASDAQ:LQDA) Dividends: History, Yield and Dates

December 20, 2023 | realmoney.thestreet.com

Liquidia price target raised by $2 at BofA, here's why

December 20, 2023 | bizjournals.com

Liquidia lands major victory in patent dispute with United Therapeutics

December 20, 2023 | finance.yahoo.com

U.S. Federal Circuit Affirms Earlier PTAB Decision to Invalidate All Claims of United Therapeutics Patent No. 10,716,793 (‘793 Patent)

December 20, 2023 | msn.com

Why Is Pulmonary Hypertension-Focused Liquidia Stock Soaring Today?

December 20, 2023 | msn.com

Liquidia jumps on win in patent case against United Therapeutics

December 19, 2023 | finance.yahoo.com

Insider Sell Alert: Chief Medical Officer Rajeev Saggar Sells 14,887 Shares of Liquidia Corp (LQDA)

December 19, 2023 | msn.com

Liquidia director buys stock worth $2M

November 28, 2023 | finance.yahoo.com

Liquidia (NASDAQ:LQDA) shareholders have earned a 35% CAGR over the last three years

November 10, 2023 | markets.businessinsider.com

Liquidia Technologies Faces Sell Rating Amid Patent Litigation, Competitive Disadvantages, and Financial Concerns

See More Headlines

Receive LQDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Liquidia and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/07/2023
Today: 12/31/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:LQDA
CUSIP: N/A
CIK: 1819576
Web: www.liquidia.com
Phone: (919) 328-4400
Fax: N/A
Employees: 63
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $16.67
High Stock Price Target: $30.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +38.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.60
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.87)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-41,010,000.00
Net Margins: -314.38%
Pretax Margin: -314.38%
Return on Equity: -82.05%
Return on Assets: -46.88%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.83
Quick Ratio: 6.83

Sales & Book Value

Annual Sales: $15.94 million
Price / Sales: 48.98
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.40 per share
Price / Book: 8.59

Miscellaneous

Outstanding Shares: 64,900,000
Free Float: 44,395,000
Market Cap: $780.75 million
Optionable: Not Optionable
Beta: -0.08

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Dr. Roger A. Jeffs Ph.D. (Age 61)
CEO & Director
Comp: $532.23k
Mr. Michael Kaseta (Age 47)
Chief Financial Officer
Comp: $627.85k
Mr. Russell Schundler (Age 48)
General Counsel & Corporate Secretary
Comp: $541.92k
Mr. William R. Kenan Jr.
Co-Founder
Dr. Ginger Denison
Co-Founder
Mr. Robert A. Lippe (Age 58)
Chief Operations Officer
Comp: $728.75k
Jennifer Almond
Director of Investor Relations & Corporate Communications
Ms. Sarah Krepp SPHR
Vice President of People & Culture
Mr. Jason Adair (Age 49)
Chief Business Officer
Dr. Tushar Shah M.D. (Age 62)
Senior Vice President of Product Development
Comp: $792.36k

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

LQDA Stock Analysis - Frequently Asked Questions

Should I buy or sell Liquidia stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Liquidia in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" LQDA shares.
View LQDA analyst ratings or view top-rated stocks.
What is Liquidia's stock price target for 2024?: 5 Wall Street analysts have issued 1-year price objectives for Liquidia's stock. Their LQDA share price targets range from $3.00 to $30.00. On average, they anticipate the company's share price to reach $16.67 in the next twelve months. This suggests a possible upside of 38.5% from the stock's current price.
View analysts price targets for LQDA or view top-rated stocks among Wall Street analysts.
How have LQDA shares performed in 2023?: Liquidia's stock was trading at $6.37 on January 1st, 2023. Since then, LQDA shares have increased by 88.9% and is now trading at $12.03.
View the best growth stocks for 2023 here.
When is Liquidia's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 21st 2024.
View our LQDA earnings forecast.
How were Liquidia's earnings last quarter?: Liquidia Co. (NASDAQ:LQDA) released its quarterly earnings data on Tuesday, November, 7th. The company reported ($0.24) EPS for the quarter, missing analysts' consensus estimates of ($0.20) by $0.04. The business had revenue of $3.68 million for the quarter, compared to analyst estimates of $4.55 million. Liquidia had a negative net margin of 314.38% and a negative trailing twelve-month return on equity of 82.05%.

What ETF holds Liquidia's stock ?: Virtus LifeSci Biotech Clinical Trials ETF holds 13,817 shares of LQDA stock, representing 0.92% of its portfolio.
What other stocks do shareholders of Liquidia own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Liquidia investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Aldeyra Therapeutics (ALDX), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO), AbbVie (ABBV), Allena Pharmaceuticals (ALNA) and NVIDIA (NVDA).
When did Liquidia IPO?: (LQDA) raised $50 million in an initial public offering (IPO) on Thursday, July 26th 2018. The company issued 4,500,000 shares at $10.00-$12.00 per share. Jefferies and Cowen acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers.
How do I buy shares of Liquidia?: Shares of LQDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LQDA) was last updated on 12/31/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Liquidia (LQDA) Stock Price, News & Analysis

Liquidia MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Liquidia Stock (NASDAQ:LQDA)

LQDA Stock Price History

LQDA Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

LQDA Stock Analysis - Frequently Asked Questions

Overall MarketRank^™